On September 30, 2024, Armistice Capital, LLC and its managing member Steven Boyd filed a Schedule 13G with the United States Securities and Exchange Commission, disclosing a 7.99% ownership stake in T2 Biosystems, Inc. This represents a total of 1,396,000 shares in the medical diagnostic company known for its innovative blood tests. The filing indicates that Armistice Capital, as the investment manager of Armistice Capital Master Fund Ltd., exercises voting and investment power over the shares held by the Master Fund. Steven Boyd, due to his role at Armistice Capital, may also be deemed to beneficially own the securities held by the Master Fund. The shares were reported based on 17,479,954 outstanding shares as of May 5, 2024. The filing asserts that the shares were acquired in the ordinary course of business and not with the purpose of changing or influencing the control of T2 Biosystems.

On September 30, 2024, Armistice Capital, LLC and its managing member Steven Boyd filed a Schedule 13G with the United States Securities and Exchange Commission, disclosing a 7.99% ownership stake in T2 Biosystems, Inc. This represents a total of 1,396,000 shares in the medical diagnostic company known for its innovative blood tests. The filing indicates that Armistice Capital, as the investment manager of Armistice Capital Master Fund Ltd., exercises voting and investment power over the shares held by the Master Fund. Steven Boyd, due to his role at Armistice Capital, may also be deemed to beneficially own the securities held by the Master Fund. The shares were reported based on 17,479,954 outstanding shares as of May 5, 2024. The filing asserts that the shares were acquired in the ordinary course of business and not with the purpose of changing or influencing the control of T2 Biosystems.